Latest news with #JAK
India Today
20-05-2025
- Health
- India Today
Scientists find common arthritis drugs could weaken immunity against Covid, flu
Drugs are meant to make us feel better, either by treating disease or easing symptoms. But sometimes, certain medicines could have unexpected side effects that could make things worse, especially during a virus outbreak.A team of scientists in Norway has now found that a commonly used group of anti-inflammatory drugs called Janus kinase inhibitors, or JAK inhibitors could actually make it easier for viruses like influenza and Covid-19 to spread inside the findings are published in NAR Molecular drugs are often used to treat chronic conditions such as rheumatoid arthritis and other autoimmune according to researchers at the Norwegian University of Science and Technology (NTNU), they may also reduce the body's natural defences against viruses."We have found a surprising and potentially serious side effect of these drugs. They can help viruses spread more easily in the body,' said Professor Denis Kainov from NTNU's Department of Clinical and Molecular simple terms, the drugs seem to weaken an important signalling process in the immune system, one that helps protect healthy cells from being this pathway is blocked, the body's ability to detect and fight viruses is research team tested the effects of JAK inhibitors on human cells taken from the lungs, eyes, and also studied mini-organs grown in the lab and used advanced gene analysis found that a drug like baricitinib, commonly used for arthritis, slows down the activity of certain genes that kick into action when a virus genes act like a security system in the body. When it's down, viruses like SARS-CoV-2 (which causes Covid) adenovirus, and influenza A can spread Ravlo, the study's lead author, said the findings show that while JAK inhibitors are useful in managing inflammation, they could carry hidden risks during viral infections, especially for people with a weak immune system.'Doctors should be careful when prescribing these drugs, particularly during times when viruses like Covid-19 or flu are circulating widely,' Ravlo the researchers also said that in controlled environments, such as during vaccine development or drug screening, this side effect might actually be instance, by making it easier to test how well a new antiviral treatment scientists are now calling for more research into how these drugs work in real-world conditions.
Yahoo
16-05-2025
- Health
- Yahoo
Alopecia Areata: Market Trends, Regulatory Framework, Clinical Trial Analysis, Epidemiology Analysis, Market Dynamics, Competitive Landscape 2025-2035
Includes Detailed Profiles of Industry Giants Eli Lilly & Company, Pfizer, Sun Pharmaceutical Industries, Arcutis Biotherapeutics, Bristol-Myers Squibb, AbbVie, Regeneron Pharmaceuticals, and Aclaris Therapeutics Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "Alopecia Areata Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035" report has been added to global market for alopecia areata treatments has experienced substantial growth due to increasing awareness, advancements in medical research, and the introduction of novel therapeutic options. One of the notable examples of current treatments is JAK inhibitors like Ritlecitinib (brand name Litfulo), which received approval by the U.S. FDA for the treatment of alopecia areata in adolescents. This approval marked a significant advancement, given the earlier limited treatment options available for those suffering from this of the key drivers of the alopecia areata market is increasing prevalence of alopecia areata. Alopecia areata affects around 2% of the global population, and its prevalence has been steadily increasing. Environmental factors like stress, pollution, and lifestyle changes are contributing to this rise. The increasing incidence of autoimmune disorders overall also means more individuals are prone to developing alopecia areata. For instance, data from the American Academy of Dermatology estimates that approximately 6.8 million people in the U.S. alone have been affected by some form of traditional treatments like corticosteroids and topical immunotherapy have been somewhat effective, but the market is now being transformed by novel therapies such as JAK inhibitors, which block the pathways involved in the autoimmune attack on hair follicles. One such breakthrough is Dupixent (dupilumab), a monoclonal antibody used to treat moderate-to-severe atopic dermatitis, which has also shown promise for patients with alopecia areata. The approval of Ritlecitinib for alopecia in adolescents in 2023 is another example of how targeted therapies are creating new hope for those affected by the the market's growth, there are several challenges that hinder the wider adoption and accessibility of treatments. Advanced treatments such as biologics (e.g., Ritlecitinib and Dupixent) are often expensive, with some costing thousands of dollars per treatment cycle. This high cost of treatment limits access for many patients, particularly in developing regions where healthcare budgets are constrained. The cost barrier is significant in countries outside the U.S. and Europe, where access to biologics is more limited. The high cost of Dupixent, for example, is a point of concern for patients seeking affordable not all patients respond the same way to therapies. While JAK inhibitors have shown great promise for some individuals with alopecia areata, they may not work equally well for everyone. The variability in patient responses has led to the need for personalized treatment plans, which complicates the management of the condition and may increase healthcare addition, many regions, particularly in Africa, Asia, and Latin America, have limited access to newer treatments due to logistical, financial, and infrastructural barriers. Although global healthcare access is improving, the availability of cutting-edge treatments like JAK inhibitors remains a challenge in these underserved Segmentation Segmentation 1: by Drug Class Corticosteroids JAK (Janus Kinase) Inhibitors Others Segmentation 2: by Region North America Europe Asia-Pacific The alopecia areata market is experiencing several key emerging trends. One notable trend is the rise of personalized medicine, where treatment plans are tailored to an individual's genetic profile, disease progression, and response to therapy. Biotech companies are increasingly investing in genetic research and biomarkers to identify which patients will benefit most from specific treatments. Another trend is the growing demand for non-invasive therapies, such as topical corticosteroids, minoxidil solutions, and low-level laser therapies. These options are becoming more popular due to their reduced side effects and ease of use, offering more affordable and accessible solutions, especially in regions with limited access to biologics. As healthcare access expands globally, biologic therapies like JAK inhibitors are also gaining traction in emerging markets, with pharmaceutical companies working to improve accessibility through patient assistance programs and distribution conclusion, the Alopecia Areata (AA) market is positioned for continued growth, driven by advancements in biologic therapies, rising awareness, and increased healthcare access worldwide. Although challenges such as high treatment costs and variability in treatment response remain, the emergence of new therapies, personalized medicine, and the global expansion of access to effective treatments are poised to enhance the management of alopecia areata. The market is also benefiting from the growing emphasis on mental health and the psychological impact of hair loss, leading to more patient-centered care. As innovation continues, both large pharmaceutical companies and smaller biotech firms will drive competition and improve the quality of life for individuals living with alopecia Topics Covered1. Markets: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Regulatory Framework1.4 Clinical Trial Analysis1.5 Epidemiology Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Alopecia Areata Market, by Drug Class, ($Million), 2023-20352.1 Corticosteroids2.2 JAK (Janus Kinase) Inhibitors2.3 Others3. Global Alopecia Areata Market, by Region, ($Million), 2023-20353.1 North America3.1.1 Key Findings3.1.2 Market Dynamics3.1.3 Market Sizing and Forecast3.1.3.1 North America Alopecia Areata Market, by Country3.1.3.1.1 U.S.3.2 Europe3.2.1 Key Findings3.2.2 Market Dynamics3.2.3 Market Sizing and Forecast3.2.3.1 Europe Alopecia Areata Market, by Country3.2.3.1.1 Germany3.2.3.1.2 U.K.3.2.3.1.3 France3.2.3.1.4 Italy3.2.3.1.5 Spain3.3 Asia Pacific3.3.1 Key Findings3.3.2 Market Dynamics3.3.3 Market Sizing and Forecast3.3.3.1 Asia Pacific Alopecia Areata Market, by Country3.3.3.1.1 Japan4. Global Alopecia Areata Market: Competitive Landscape and Company Profiles4.1 Key Developments and Strategies4.1.1 Mergers and Acquisitions4.1.2 Synergistic Activities4.1.3 Business Expansions and Funding4.1.4 Product Launches and Approvals4.1.5 Other Activities4.2 Company Profiles4.2.1 Eli Lilly and Company4.2.1.1 Overview4.2.1.2 Top Products / Product Portfolio4.2.1.3 Target Customers/End-Users4.2.1.4 Key Personnel4.2.1.5 Analyst View4.2.2 Pfizer Inc.4.2.3 Sun Pharmaceutical Industries Ltd.4.2.4 Arcutis Biotherapeutics4.2.5 Bristol-Myers Squibb4.2.6 AbbVie4.2.7 Regeneron Pharmaceuticals4.2.8 Aclaris TherapeuticsFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
15-05-2025
- Health
- Medscape
Risks and Benefits of JAK Inhibitors for Vitiligo
In a meta-analysis, topical Janus kinase (JAK) inhibitors demonstrated promising but non-significant results for vitiligo, with patients administered JAK inhibitors having a higher likelihood of achieving a 75% improvement in facial repigmentation compared with those using a vehicle cream. However, single-arm trials and case reports indicated significant repigmentation with both oral and topical formulations. Oral JAK inhibitors were associated with potential adverse effects such as risks for immunosuppression and cardiovascular events. METHODOLOGY: Researchers conducted three meta-analyses of 19 studies to determine the safety and efficacy of JAK inhibitors in patients with vitiligo treated with oral or topical JAK inhibitors with or without conventional therapy. Three distinct analyses were conducted, with data analysed from randomised controlled trials (RCTs), four single-arm trials, and a novel cohort of JAK inhibitor–treated patients from case reports and case series. RCTs used topical ruxolitinib cream with placebo or vehicle cream as a comparator. Single-arm trials mostly used topical JAK inhibitors, whereas the novel cohort used oral JAK inhibitors. Primary efficacy outcomes were a 75% improvement in the Facial Vitiligo Area Scoring Index (F-VASI75), mean percentage change in the VASI, and percentage of repigmentation in vitiligo lesions. TAKEAWAY: A meta-analysis of three RCTs showed that patients treated with topical JAK inhibitors were more likely to achieve F-VASI75 than those using vehicle cream (risk ratio [RR], 3.47; 95% CI, 0.98-12.22; P = .051), with no significant difference in adverse events between groups (RR, 1.27; 95% CI, 0.88-1.82). = .051), with no significant difference in adverse events between groups (RR, 1.27; 95% CI, 0.88-1.82). The pooled analysis of four single-arm trials demonstrated a mean percentage change in the VASI of 43.79% (95% CI, 0.71-0.93; P < .001). < .001). An analysis of the novel cohort revealed significantly increased repigmentation in patients treated with JAK inhibitors alone (48.7%; P = .0018) and in those treated with JAK inhibitors and narrowband ultraviolet B therapy (63.7%; P < .0001). = .0018) and in those treated with JAK inhibitors and narrowband ultraviolet B therapy (63.7%; < .0001). Topical JAK inhibitors generally exhibited a more favourable safety profile; however, oral JAK inhibitors were associated with risks for immunosuppression, cardiovascular events, and haematopoietic disorders. IN PRACTICE: "Although topical ruxolitinib demonstrated encouraging outcomes, its results in RCTs did not reach statistical significance. However, findings from single-arm trials and case studies revealed substantial repigmentation, particularly when oral JAKis [JAK inhibitors] were administered alongside other therapeutic interventions," the authors wrote. "Future RCTs are essential to evaluate long-term safety, refine optimal application protocols and establish standardised outcome measures for combination therapies, ultimately improving treatment strategies for vitiligo," they concluded. SOURCE: This study was led by Alzahra A. Mohammed, Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University in Budapest, Hungary. It was published online on May 07, 2025, in Dermatology and Therapy . LIMITATIONS: The analysis was constrained by the small number of RCTs available and challenges in data collection from case reports due to heterogeneity in outcome reporting. Clinically meaningful thresholds for improvement were inconsistently followed across case reports and single-arm trials, limiting their integration. Analysis of the novel cohort was further limited by potential reporting biases and small sample size, and follow-up durations of single-arm trials and the novel cohort were insufficient for a comprehensive analysis of adverse events or long-term safety concerns. DISCLOSURES: This study received funding through a grant from the EU Horizon 2020 research and innovation programme. The Hungarian Centre of Excellence for Molecular Medicine covered publication fees. The authors reported no relevant conflicts of interest.
Time of India
02-05-2025
- Health
- Time of India
New study finds tofacitinib effective and affordable for refractory atopic dermatitis
New Delhi: New Delhi: Tofacitinib , a Janus kinase (JAK) inhibitor drug, used either as a standalone treatment or alongside other drugs to address moderate to severe cases of rheumatoid arthritis and ankylosing spondylitis, demonstrates effectiveness in managing refractory atopic dermatitis (AD). Tired of too many ads? go ad free now This was revealed in a study published in the Indian Dermatology online journal. Atopic dermatitis (AD) presents as a long-term, recurring inflammatory disorder of the skin, and its characteristic itching significantly affects patients' daily living standards. The research was conducted at the department of dermatology, venereology and leprosy in Atal Bihari Vajpayee Institute of Medical Sciences and Research Institute and Dr Ram Manohar Lohia Hospital. The results established that people who previously showed no response to standard systemic treatments, including oral corticosteroids, cyclosporine and azathioprine, exhibited significant clinical improvement when administered tofacitinib exclusively. The progress was evaluated through decreased Scoring Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI), and Numerical Rating Scale (NRS) measurements at 4-week and 8-week intervals. The principal investigator of the study and dermatologist at RML Hospital, professor Kabir Sardana, explained that their main goal was to evaluate how well tofacitinib worked and its side effects in patients with difficult-to-treat moderate-to-severe AD. Additionally, they aimed to analyse the treatment costs between tofacitinib and dupilumab (approved by the Central Drugs Standard Control Organisation, India) for moderate and severe AD cases. Tired of too many ads? go ad free now The research indicated an average disease duration of three years. Patients displayed moderate to severe pruritus, excoriations, erythema, oozing and crusting. All participants had previously experienced treatment failure or intolerance to systemic therapy; 50% of patients also had other atopic conditions and bronchial asthma. The researchers continued treatment with topical corticosteroids, moisturiser and topical calcineurin inhibitors alongside tofacitinib. Improvements were observed in pruritus, sleep quality, affected body surface area, erythema, excoriation, papulation/edema and lichenification, with notable severity score reductions at four weeks and eight weeks of therapy. Dr Sardana said that EASI 90 was attained by 66% of patients within 8 weeks, with one patient experiencing treatment failure. Patients achieved complete or near-complete disease resolution in an average of 6.1 weeks (ranging from 3-8 weeks). Disease recurrence was observed in 36.3% of patients. Adverse reactions occurred in 41.6% of patients, including herpes zoster, dyslipidemia, anaemia, impetigo, and thrombocytosis. The financial comparison revealed that dupilumab (a monoclonal antibody used to treat various allergic conditions, including atopic dermatitis, asthma, and nasal polyps) therapy costs 122 times more than tofacitinib treatment over an 8-week period.
Yahoo
05-03-2025
- Health
- Yahoo
Canine Atopic Dermatitis Market to Cross US$ 431.0 Mn by 2035 as Pet Dermatology Advances Gain Traction
The Canine Atopic Dermatitis Market is poised for significant growth from 2025 to 2035, driven by increasing pet healthcare awareness and advanced treatment options. Key product types include glucocorticoids, immunosuppressants, monoclonal antibodies, calcineurin inhibitors, and Janus kinase (JAK) inhibitors, administered via topical, oral, and injectable routes. Rising cases of canine allergies and innovations in dermatological treatments are fueling market expansion. Wilmington, Delaware, Transparency Market Research Inc. –, March 05, 2025 (GLOBE NEWSWIRE) -- The Canine Atopic Dermatitis Market (Marché de la dermatite atopique canine) is expected to expand steadily, reaching US$ 431.0 Mn by 2035 from US$ 231.4 Mn in 2024, growing at a CAGR of 5.8% from 2025 to 2035. Increasing pet ownership, rising awareness of dermatological conditions, and advancements in treatment options are key drivers. The demand for monoclonal antibodies, JAK inhibitors, and immunosuppressants is growing, with topical, oral, and injectable treatments gaining traction. Emerging therapies and veterinary innovations are set to shape market dynamics over the forecast period. Industry Overview The Canine Atopic Dermatitis Industry is experiencing steady growth, driven by rising pet ownership, increasing awareness of pet health, and advancements in veterinary dermatology. As more pet owners seek effective treatments for chronic skin conditions in dogs, the demand for innovative biologics, immunomodulators, and topical therapies is on the rise. Discover What's Driving the Canine Atopic Dermatitis Market- Request a Sample Report! Market Drivers Fueling Growth Rising Pet Ownership & Spending on Veterinary Care – The global increase in pet adoption, coupled with higher spending on pet health and wellness, is fueling market growth. Increased Awareness of Skin Allergies in Dogs – Veterinarians and pet owners are becoming more knowledgeable about chronic skin conditions and the importance of early diagnosis and treatment. Advancements in Veterinary Pharmaceuticals – New biologics, monoclonal antibodies, and immunotherapy treatments are improving long-term management of canine atopic dermatitis. Growth in E-Commerce & Online Pet Pharmacies – The availability of prescription treatments, medicated shampoos, and supplements through online pet healthcare platforms is making treatments more accessible. Demand for Natural & Hypoallergenic Solutions – Pet owners are seeking natural, steroid-free, and holistic treatments, boosting the market for nutraceuticals and dermatological supplements. Who's Leading the Market? Key Players to Watch The global Canine Atopic Dermatitis Market is highly competitive, with several key players driving innovation and market growth. Leading companies in this space include Zoetis, Merck & Co., Inc., Elanco, Boehringer Ingelheim International GmbH, Virbac Corporation, and Vetoquinol, all of which are actively involved in developing advanced treatment solutions. Additionally, TORAY INDUSTRIES, INC., Biocelix, Dechra Pharmaceuticals PLC, Bioiberica S.A.U., Ceva, and Bimeda Corporate play a significant role in the market, offering a diverse range of products aimed at managing and treating canine atopic dermatitis. These companies focus on research and development, strategic partnerships, and expanding their product portfolios to meet the growing demand for effective dermatological treatments in the veterinary sector. Recent Developments Zoetis introduced a new biologic therapy targeting CAD symptoms with long-lasting relief. Elanco acquired a veterinary dermatology company to expand its treatment portfolio. Virbac launched a next-generation hypoallergenic diet to aid in managing atopic dermatitis in dogs. Dechra Pharmaceuticals secured regulatory approvals for a new corticosteroid treatment. Key Players' Growth Strategies Leading market players are employing strategies such as: Product Innovation: Development of advanced biologics, novel immunotherapies, and improved topical solutions. Strategic Partnerships: Collaborations with veterinary clinics and research institutions. Geographic Expansion: Entry into emerging markets to capitalize on growing pet healthcare awareness. Mergers & Acquisitions: Strengthening portfolios through acquisitions of niche dermatology firms. Treatment Options Treatments for Canine Atopic Dermatitis are categorized into three main types: Pharmaceuticals: Corticosteroids, antihistamines, and immune-modulating drugs are the primary pharmaceutical treatments. Newer therapies such as Apoquel (Oclacitinib) and Cytopoint (monoclonal antibody therapy) have revolutionized the treatment landscape by providing long-lasting relief with fewer side effects. Topical Treatments: Medicated shampoos, sprays, and lotions play a key role in soothing affected skin and reducing inflammation. These treatments are often combined with systemic drugs to manage flare-ups. Dietary Modifications: For dogs with food-triggered atopic dermatitis, hypoallergenic diets or specific nutrient-rich formulations can reduce symptoms by limiting exposure to food allergens. With ongoing innovations in immunotherapy and targeted treatments, the future of CAD management is expected to provide better efficacy, fewer side effects, and more personalized approaches. The industry will continue evolving as pet owners demand safer, more effective, and cost-efficient solutions. Comparison of Leading Therapies Treatment Type Mechanism Duration of Action Common Brands Cytopoint Monoclonal Antibody IL-31 Inhibition 4–8 Weeks Zoetis Apoquel JAK Inhibitor Blocks Itch & Inflammation Pathways Daily Elanco Cyclosporine Immunosuppressant T-cell Modulation Long-term Atopica (Virbac) Get Customized Insights & Analysis for Your Business Needs: Market Segmentation: Where the Growth Lies By Treatment Type Monoclonal Antibodies (mAbs) – Targeted therapies like Cytopoint, reducing itching and inflammation with long-lasting effects. Immunosuppressants & Corticosteroids – Popular treatments such as Apoquel, providing rapid relief for allergic reactions. Topical Therapy – Medicated shampoos, sprays, and ointments for direct skin application. Nutraceuticals & Dietary Supplements – Omega-3 fatty acids, probiotics, and skin-supportive diets aiding in long-term skin health. By Distribution Channel Veterinary Clinics & Hospitals – The go-to source for diagnosis and prescription treatments. Retail & Online Pharmacies – E-commerce growth is making skin care solutions easily accessible. Pet Specialty Stores – Increased demand for hypoallergenic pet care products and supplements. By Region Region Market Share (%) Key Drivers North America 40% High pet adoption & advanced veterinary care Europe 25% Increasing awareness & premium pet care spending Asia-Pacific 20% Rising pet ownership & urbanization Latin America 10% Growth in veterinary infrastructure Middle East & Africa 5% Limited market, but potential for growth Future Outlook & Prospective The future of the Canine Atopic Dermatitis market looks promising, with continued advancements in treatment methodologies and increasing pet healthcare expenditures. Emerging trends, such as precision medicine and telehealth veterinary services, will further propel market growth. By 2035, innovative solutions and increased awareness will reshape the industry landscape, offering expanded opportunities for key players and stakeholders. Why Invest in This Market? High-Growth Segment in Pet Healthcare – Rising awareness and increased spending on pet well-being make this a lucrative industry. Innovative Treatments & Expanding Product Lines – Newer biologics, AI-driven solutions, and holistic therapies are creating long-term opportunities. Booming E-Commerce & Telehealth Accessibility – Convenient access to pet treatments is expanding the customer base. The Canine Atopic Dermatitis Market is evolving beyond traditional therapies, embracing next-gen biologics, personalized treatments, and holistic care. As pet owners seek the best solutions for their furry companions, veterinary dermatology is set for an exciting future. Decision-Making Summary- For investors, distributors, and industry stakeholders, this report serves as a strategic tool to navigate the growing Canine Atopic Dermatitis market. With increasing pet ownership and advancements in veterinary dermatology, the sector offers promising opportunities. Companies investing in innovation, geographic expansion, and strategic collaborations are poised for significant growth. By leveraging the insights provided in this report, businesses can make well-informed decisions to enhance their market positioning and profitability. Purchase the Full Market Report Today: Important FAQs- 1. What are the major treatment options available for Canine Atopic Dermatitis? Major treatment options include biologics, antihistamines, corticosteroids, immunosuppressants, and topical therapies. 2. What is the expected growth rate of the Canine Atopic Dermatitis market? The market is projected to grow at a CAGR of 5.8% from 2025 to 2035. 3. Which regions dominate the Canine Atopic Dermatitis market? North America and Europe currently lead the market, with Asia-Pacific showing significant growth potential. 4. What are the key challenges in the market? High treatment costs and limited awareness in developing regions are major challenges. 5. How are companies innovating in this space? Companies are focusing on advanced biologics, improved immunotherapies, and strategic acquisitions to enhance their market position. Explore Latest Research Reports by Transparency Market Research: Neurovascular Devices Market (Marché des dispositifs neurovasculaires) is projected to reach a valuation of US$ 7 Billion by 2033. COVID-19 Vaccine Market (Marché du vaccin COVID-19) is projected to reach more than US$ 9.9 Billion by the end of 2031. About Transparency Market Research Transparency Market Research, a global registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact: Transparency Market Research HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA – Canada Toll Free: 866-552-3453Website: Email: sales@ Us: LinkedIn| Twitter| Blog | YouTubeSign in to access your portfolio
